Gossamer Bio Cuts Half Its Staff Following Disappointing Trial Results
SOURCENews reportView the filing ↗
What we know
Based on news reporting.
Summary
Gossamer Bio, Inc. has laid off approximately 50 employees, which constitutes half of its workforce, following disappointing results from a clinical trial that led to a significant drop in stock prices. The layoffs are part of a restructuring effort aimed at reducing costs and refocusing the company's strategic priorities. This decision comes in the wake of challenges faced in the biotech sector, particularly concerning the efficacy of their drug candidates. The company is now looking to streamline operations and improve its financial standing after the trial setbacks.
LayoffTalk has tracked 2 layoff events at Gossamer Bio, Inc. since March 2026, including 65 jobs documented in official WARN filings, with 1 additional event known from news reporting.
Comments (0)
Anonymous by default. Be kind — people reading this may be going through it right now.
No comments yet. Be the first to share your thoughts.
Affected by this?
Share your story anonymously — it helps others reading this feel less alone.
Share your story →More layoffs at Gossamer Bio, Inc.
Recent tracked events at this company.